Effect of Blocking Angiotensin II Receptor Subtype on Rat Sympathetic Nerve Function

Pancras C. Wong, Roberta Bernard, and Pieter B.M.W.M. Timmermans

This study examined effects of nonpeptide angiotensin II (Ang II) receptor subtype antagonists on the interaction of sympathetic function and Ang II in pithed rats. Effects of spinal cord stimulation (0.5-4 Hz) and norepinephrine (0.3-3 µg/kg i.v.) on mean arterial pressure (recorded with a carotid arterial catheter), cardiac output (measured with an electromagnetic flowmeter and flow probe around the thoracic ascending aorta), total peripheral resistance, and heart rate were determined. The subtype 1-selective Ang II receptor antagonist losartan (previously known as DuP 753) at 10 mg/kg i.v. blocked the hemodynamic responses to Ang II at 1 µg/kg i.v. It inhibited mean arterial pressure and total peripheral resistance responses but not cardiac output and heart rate responses to spinal cord stimulation. In contrast, it reduced mean arterial pressure and cardiac output responses but not total peripheral resistance and heart rate responses to intravenous norepinephrine. Given at 100 mg/kg i.v., the subtype 2-selective receptor antagonist PD123177 did not reduce hemodynamic responses to intravenous Ang II, spinal cord stimulation, and intravenous norepinephrine. These results suggest that endogenous Ang II facilitates the release of norepinephrine from sympathetic nerve terminals in the vasculature of pithed rats. Similar to the Ang II receptor in vascular smooth muscle, the prejunctional Ang II receptor in pithed rats appears to be of subtype 1. (Hypertension 1992;19:663-667)

KEY WORDS • angiotensin receptors • antihypertensive therapy • renin-angiotensin system • sympathetic nervous system

It is well known that exogenous angiotensin II (Ang II) enhances vasoconstrictor and vascular contractile responses to sympathetic nerve stimulation. The adrenergic potentiation by Ang II has been commonly attributed to increased release of norepinephrine through the activation of prejunctional Ang II receptors, inhibition of the reuptake of norepinephrine from sympathetic nerve terminals, and increased vascular responsiveness to norepinephrine. By blockade of the influence of the renin-angiotensin system with angiotensin converting enzyme inhibitors or Ang II receptor antagonists, the adrenergic facilitating effect of endogenous Ang II has also been shown.

Recently, we as well as others demonstrated that Ang II receptors may be subdivided pharmacologically into two subtypes, i.e., subtype 1 (AT₁) and subtype 2 (AT₂) (for review, see References 9 and 10). In anesthetized dogs, the AT₁-selective receptor antagonist losartan (previously known as DuP 753, 2-n-butyl-4-chloro-5-(hydroxymethyl)-l-[(2'-(1/-tetrazol-5-yl)biphenyl-4-yl)methyl]imidazole, potassium salt) blocked the renal vasoconstrictor response to renal nerve stimulation but not to norepinephrine, whereas the AT₂-selective receptor antagonist PD123177 [(4-amino-3-methylphenyl)methyl]-5-(diphenylacetyl)-4,5,6,7-tetrahydro-1Himidazo[4,5-c]pyridine-6-carboxylic acid] was ineffective. This result suggests that endogenous Ang II enhances renal adrenergic function at the prejunctional site through the activation of AT₁ receptors. To further substantiate this finding, we examined the effects of losartan and PD123177 on hemodynamic responses to sympathetic nerve stimulation in the pithed rat, a model commonly used to study the adrenergic potentiation of endogenous Ang II.

Methods

The pithed rat model, described by Kaufman and Vollmer, was used in this study with some modifications. Male CD Sprague-Dawley rats (250-400 g; Charles River Laboratories, Inc., Kingston, N.Y.) were anesthetized with hexobarbital (150 mg/kg i.p.), adrenalectomized, pithed, and artificially respirated. Atropine (2 mg/kg i.p.) was given, and both vagus nerves were cut to prevent any parasympathetic effect. The carotid artery and jugular vein were cannulated for arterial pressure measurement with a pressure transducer (P23ID, Gould Inc., Oxnard, Calif.) and intravenous injection of drugs, respectively. Tubocurarine (1 mg/kg i.v.) was given to prevent voluntary muscle activity. A calibrated electromagnetic flow probe connecting to a flowmeter (Carolina Medical Electronics, Inc., King, N.C.) was placed on the thoracic ascending aorta to measure cardiac output (CO) (excluding coronary blood flow).

Mean arterial pressure (MAP) was determined as the sum of diastolic blood pressure and one third of the pulse pressure. CO was expressed as milliliters per minute per kilogram of body weight. Total peripheral resistance (TPR) was calculated by dividing MAP by CO and then multiplying by 100. Blood pressure and
TABLE 664

Hypertension

Baseline hemodynamics

II Before and After Losartan or PD123177

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Losartan Before</th>
<th>Losartan After</th>
<th>PD123177 Before</th>
<th>PD123177 After</th>
</tr>
</thead>
<tbody>
<tr>
<td>MAP (mm Hg)</td>
<td>45±2</td>
<td>33±1*</td>
<td>49±3</td>
<td>48±1</td>
</tr>
<tr>
<td>CO (ml/min/kg)</td>
<td>115±4</td>
<td>88±5*</td>
<td>124±7</td>
<td>119±6</td>
</tr>
<tr>
<td>TPR (units)</td>
<td>39±1</td>
<td>38±2</td>
<td>40±2</td>
<td>41±2</td>
</tr>
<tr>
<td>HR (bpm)</td>
<td>325±7</td>
<td>303±5*</td>
<td>332±12*</td>
<td></td>
</tr>
</tbody>
</table>

* p<0.05 compared with pretreatment control (analysis of variance).

Values are mean±SEM; n=10 per group for baseline hemodynamic data (pooled data from groups treated with spinal cord stimulation and norepinephrine) and n=5 per group for angiotensin II (Ang II) response data. Ang II was given at 1 µg/kg i.v., losartan at 10 mg/kg i.v., and PD123177 at 100 mg/kg i.v. MAP, mean arterial pressure; CO, cardiac output; TPR, total peripheral resistance; HR, heart rate; bpm, beats per minute.

CO were recorded on a polygraph (Grass Instrument Co., Quincy, Mass.) and analyzed with a digital computer (Buxco Electronics, Sharon, Conn.).

All rats were allowed 15–20 minutes to recover from preparative surgery for stabilization of MAP and CO. In the first group of experiments, the spinal cord was stimulated electrically at 0.5, 1, 2, and 4 Hz for 15 seconds at 50 V with square waves of 2-msec duration delivered by a Grass stimulator with the pithing rod as the cathode and a hypodermic needle inserted under the skin of the hind limb as the anode. Sufficient time was allowed between stimulation periods to ensure that MAP and CO had completely returned to the control values. After the control frequency–hemodynamic–response curve for spinal cord stimulation was obtained, rats were treated with saline (1 ml/kg i.v.), losartan (10 mg/kg i.v.), or PD123177 (100 mg/kg i.v.). Fifteen minutes later, hemodynamic responses to spinal cord stimulation were again determined.

In the second group of experiments, a similar protocol as described above was followed except that in place of electrical stimulation, norepinephrine at 0.3, 1, and 3 µg/kg i.v. and Ang II at 1 µg/kg i.v. were given before and 15 minutes after the injection of saline, losartan at 10 mg/kg i.v., or PD123177 at 100 mg/kg i.v.

Losartan and PD123177 were dissolved in saline and injected intravenously at 1 ml/kg. Ang II and norepinephrine were given intravenously in saline at 0.1 ml/kg. Ang II and norepinephrine were obtained from Sigma Chemical Co., St. Louis, Mo. Losartan and PD123177 were synthesized at The Du Pont Merck Pharmaceutical Co., Wilmington, Del.

Statistical analysis used was analysis of variance for two-factor experiments with repeated measurements. The level of significance was taken at a value of p<0.05. All data are expressed as mean±SEM.

Results

As shown in Table 1, losartan at 10 mg/kg i.v. lowered baseline MAP, which was due to a decrease in baseline CO. PD123177 at 100 mg/kg i.v. did not alter baseline MAP, CO, or TPR. Both compounds slightly reduced heart rate (HR). Saline vehicle (n=10) did not alter baseline MAP, CO, or TPR (data not shown) but slightly decreased HR from 292±8 to 276±8 beats per minute (p<0.05). Thus, the slight reduction of baseline HR by losartan and PD123177 may not be pharmacologically relevant. Ang II at 1 µg/kg i.v. increased MAP, CO, TPR, and HR (Table 1). These responses to Ang II were blocked by losartan but not by PD123177.

As shown in Figure 1, electrical stimulation of the spinal cord caused a frequency-dependent increase in MAP, which is due to increases in CO and TPR. Losartan at 10 mg/kg i.v. reduced the pressor responses to spinal cord stimulation by a reduction of the TPR but not the CO component. The HR response was not changed significantly by losartan. On the contrary, PD123177 at 100 mg/kg i.v. did not alter the hemodynamic responses to spinal cord stimulation. Saline vehicle did not change the hemodynamic responses to spinal cord stimulation (data not shown).

Norepinephrine caused a dose-dependent increase in MAP, CO, TPR, and HR (Figure 2). Losartan at 10 mg/kg i.v. reduced the MAP and CO responses to norepinephrine significantly but not the TPR and HR responses. The tendency for a reduction of the TPR response to norepinephrine at 0.3 µg/kg i.v. after losartan was not significant. PD123177 at 100 mg/kg i.v. increased the MAP and TPR responses to norepinephrine significantly (Figure 2). Saline vehicle did not change the hemodynamic responses to norepinephrine (data not shown).

Discussion

Two distinct high-affinity binding sites for Ang II have recently been identified in various tissues by radioligand receptor binding and autoradiographic studies (for review, see References 9 and 10). The Ang II binding sites that have high affinity for losartan or its analogues are classified as AT₁ receptor, whereas those that have high affinity for PD123177, PD123319, CGP42112A, and pNH₂-[Phe₆]Ang II are defined as AT₂ receptor. Most of the known effects of Ang II, including vasoconstriction, adrenal aldosterone and catecholamine secretion, and water drinking, were blocked by the AT₁ receptor antagonist losartan (or its analogues), whereas the AT₂ receptor antagonist PD123177 (or its analogues) was ineffective. This study shows that losartan at 10 mg/kg i.v. almost completely abolished the hemodynamic responses to Ang II, whereas PD123177 at 100 mg/kg i.v. did not alter these effects of Ang II in pithed rats. This confirms previous findings that the vasoconstrictor effect of Ang II in rats is mediated by the AT₁ receptor.

Losartan but not PD123177 decreased baseline MAP in the pithed rat, which is mainly due to a reduction in CO. This is consistent with previous studies showing that the hypotensive effect of saralasin, a peptide Ang II receptor antagonist, in the pithed rat was due to a reduction of CO without alteration of TPR. Apparently, in the absence of tonic sympathetic discharge, Ang II does not contribute to TPR in the pithed rat. The positive chronotropic effect of Ang II (see Table 1) may not be related to the maintenance of CO, because
the high peak plasma Ang II level after bolus intravenous
ous Ang II may not be physiologically relevant. In fact, in captopril-treated pithed rats, intravenous infusion of
Ang II at a dose that reversed the reduced CO to
precaptopril levels (i.e., presumably returned the de-
pressed plasma Ang II level to control level) did not
alter HR.5 As Ang II does not have a direct positive
cardiac contractile effect in rats,16 it is likely that Ang II
maintains CO by inducing venous constriction5,17
through the activation of the AT1 receptors.

Our present study confirms previous findings5,6 that
stimulation of the sympathetic neurons in the pithed rat
raises blood pressure by increasing CO and TPR. Block-
ade of the AT1 receptors with losartan significantly
attenuated the pressor response to sympathetic nerve
stimulation. This is solely due to a reduction of the rise
in TPR. CO and HR responses to sympathetic nerve
stimulation were not significantly affected. Similar results
were also reported in rats with the angiotensin
converting enzyme inhibitor captopril and the peptide
Ang II receptor antagonist saralasin.4-6 One possible
explanation suggested by Kaufman and Vollmer6 is that
circulating Ang II gains ready access to the vascular but
not to the cardiac sympathetic synapses in the pithed
rat. However, our previous study with a monoclonal Ang
II antibody suggests that vascular-formed Ang II but not
circulating Ang II enhances the sympathetic vascular
response in the pithed rat.6 An alternate explanation is
that the cardiac prejunctional Ang II receptor in rats
may be absent or not function in vivo.

Norepinephrine injected intravenously in the pithed
rat caused dose-dependent increases in MAP. Similar to
sympathetic nerve stimulation, the pressor response to
norepinephrine was accounted for increases in CO
and TPR. Inhibition of the AT1 receptors with losartan
also reduced the pressor response to norepinephrine.
However, unlike the case with sympathetic nerve stim-
ulation, the reduction of the CO component but not the
TPR component contributed to the decrease in pressor
response to norepinephrine. The mechanisms account-
ning for the reduction in CO increases to norepinephrine
by losartan are not clear. However, it is not likely that
losartan affects the cardiac response to β-adrenergic
receptor stimulation, because it did not alter the tachy-
cardiac response to isoprotenerol18 and the cardiac
response to sympathetic nerve stimulation as shown in
this study. Previous studies reported that captopril and
saralasin reduced the pressor effect of norepinephrine
by decreasing the TPR but not the CO response in the
pithed rat.5,6 The reasons for the discrepant results

**FIGURE 1.** Line plots show mean arterial pressure, cardiac output, total peripheral resistance, and heart rate responses to spinal
cord stimulation in pithed rats before and after losartan or PD123177. Values represent mean±SEM; n=5 per group; p<0.05
compared with corresponding pretreatment control (analysis of variance).
between these studies are not obvious but may be due to other actions of captopril and saralasin. For instance, unlike saralasin and captopril, losartan does not possess the Ang II agonistic and bradykinin potentiating effects, respectively. Interestingly, PD123177 enhanced the pressor response to norepinephrine by increasing the TPR without altering CO. Apparently, this is not due to a nonselective increased responsiveness of the vasculature to vasoconstriction, as the vasoconstrictor effects of Ang II and sympathetic nerve stimulation were not changed by PD123177. The pharmacological significance of this enhancement by PD123177 is not known. Perhaps additional studies using more selective α-adrenergic receptor agonists and different subtype Ang II receptor antagonists may clarify these findings.

In summary, as the TPR response elicited by sympathetic nerve stimulation but not the TPR response induced by intravenous norepinephrine was reduced by losartan, a presynaptic rather than a postsynaptic inhibition may account for the observed reduced responses to sympathetic nerve stimulation in the pithed rat. Furthermore, the presynaptic Ang II receptors in the vasculature of the pithed rat are AT1 receptors, which is consistent with our previous finding that the renal presynaptic Ang II receptors in anesthetized dogs are of the AT1 type.

References


Effect of blocking angiotensin II receptor subtype on rat sympathetic nerve function.

P C Wong, R Bernard and P B Timmermans

Hypertension. 1992;19:663-667
doi: 10.1161/01.HYP.19.6.663

Hypertension is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 1992 American Heart Association, Inc. All rights reserved.
Print ISSN: 0194-911X. Online ISSN: 1524-4563

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://hyper.ahajournals.org/content/19/6_Pt_2/663

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Hypertension can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Hypertension is online at:
http://hyper.ahajournals.org/subscriptions/